Anticorps Polyclonal de lapin anti-CDR2
CDR2 Polyclonal Antibody for WB, IHC, ELISA
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain, souris
Applications
WB, IP, IHC, ELISA
Conjugaison
Non conjugué
N° de cat : 11611-2-AP
Synonymes
Galerie de données de validation
Applications testées
| Résultats positifs en WB | tissu cérébral humain, cellules Y79 |
| Résultats positifs en IHC | tissu de cancer du sein humain il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0. |
Dilution recommandée
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| Immunohistochimie (IHC) | IHC : 1:20-1:200 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Applications publiées
| WB | See 1 publications below |
| IP | See 1 publications below |
Informations sur le produit
11611-2-AP cible CDR2 dans les applications de WB, IP, IHC, ELISA et montre une réactivité avec des échantillons Humain, souris
| Réactivité | Humain, souris |
| Réactivité citée | Humain |
| Hôte / Isotype | Lapin / IgG |
| Clonalité | Polyclonal |
| Type | Anticorps |
| Immunogène | CDR2 Protéine recombinante Ag2183 |
| Nom complet | cerebellar degeneration-related protein 2, 62kDa |
| Masse moléculaire calculée | 454 aa, 52 kDa |
| Poids moléculaire observé | 62 kDa |
| Numéro d’acquisition GenBank | BC017503 |
| Symbole du gène | CDR2 |
| Identification du gène (NCBI) | 1039 |
| Conjugaison | Non conjugué |
| Forme | Liquide |
| Méthode de purification | Purification par affinité contre l'antigène |
| Tampon de stockage | PBS with 0.02% sodium azide and 50% glycerol |
| Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
Patients with paraneoplastic cerebellar degeneration (PCD) carry a characteristic antibody called anti-Yo. On Western blot analysis of Purkinje cells and tumor tissue from CD patient, the anti-Yo sera react with at least 2 antigens, a major species of 62 kD called CDR62 or CDR2 [PMID:18045792]. CDR2 is partly characterized, as CDR2 through its leucine zipper motif has been demonstrated to interact with c-myc, with cell cycle-related proteins and with a protein kinase, indicating that CDR2 is involved in signal transduction and gene transcription. Furthermore, CDR2 has been found to attenuate hypoxic response in renal cell carcinoma, and recent data suggest a role for CDR2 and c-myc in mitosis in cycling cells [PMID:21080165].
Protocole
| Product Specific Protocols | |
|---|---|
| WB protocol for CDR2 antibody 11611-2-AP | Download protocol |
| IHC protocol for CDR2 antibody 11611-2-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Avis
The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.
FH anwesh (Verified Customer) (11-11-2019) | CDR2 was successfully IP'ed from A549 cells. The antibody had not background bands.
|
FH anwesh (Verified Customer) (07-29-2019) | The protein was found at the right size and no additional background bands were observed around the size range. Perfect!
![]() |




